Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutrition, Prebiotics, Probiotics, and Prokinetics.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or primary data
PubMed 40296627 · doi:10.2174/0113816128373584250407134451
What was done
This narrative review synthesized literature on the pathophysiology, diagnostic challenges, and nutritional consequences of small intestinal bacterial overgrowth (SIBO), examining the roles of dietary interventions, prebiotics, probiotics, and prokinetic agents in prevention and treatment.
What was found
The abstract reports no numerical data or quantitative outcomes. It describes qualitative associations between SIBO and obesity, celiac disease, irritable bowel syndrome, inflammatory bowel disease, and cirrhosis, alongside malabsorption of fats, carbohydrates, proteins, and iron. Modulating the microbiota and restoring migrating motor complex activity with prokinetics are identified as potential therapeutic avenues.
Why it matters
The review outlines adjunctive, non-antibiotic management options for SIBO that focus on gastrointestinal motility, nutritional repletion, and microbiota modulation.
Limits
The abstract contains no primary data, sample sizes, or systematic review methodology. SIBO diagnostic criteria remain heterogeneous, and evidence linking SIBO to obesity and BMI remains conflicting.
Cited by
- contradicts GLP-1 receptor agonists slow motility through the gut, which helps with conditions such as SIBO, Candida, and H. pylori.